ACHV - Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

• Achieve Life Sciences ( NASDAQ: ACHV ) said it had begun screening subjects in a Phase 2 clinical trial for nicotine e-cigarette cessation.
• The mid-stage trial, dubbed ORCA-V1, will evaluate the efficacy and safety of 3mg cytisinicline dosed 3 times daily vs. placebo in about 150 adult e-cigarette users at 5 clinical trial locations in the United States.
• The company's trial is being supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health through grant funding which was awarded in two phases totaling $2.8M.

For further details see: